X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs IPCA LABS - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD IPCA LABS ORCHID PHARMA LTD/
IPCA LABS
 
P/E (TTM) x 0.2 35.6 0.5% View Chart
P/BV x 0.2 3.4 6.5% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ORCHID PHARMA LTD   IPCA LABS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
IPCA LABS
Mar-17
ORCHID PHARMA LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs194643 30.2%   
Low Rs35503 7.0%   
Sales per share (Unadj.) Rs276.5254.4 108.7%  
Earnings per share (Unadj.) Rs-79.216.1 -492.9%  
Cash flow per share (Unadj.) Rs-43.529.8 -145.9%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs53.9194.6 27.7%  
Shares outstanding (eoy) m70.45126.20 55.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.3 18.4%   
Avg P/E ratio x-1.435.7 -4.1%  
P/CF ratio (eoy) x-2.619.2 -13.7%  
Price / Book Value ratio x2.12.9 72.1%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m8,06772,300 11.2%   
No. of employees `0002.813.3 21.0%   
Total wages/salary Rs m2,5276,960 36.3%   
Avg. sales/employee Rs Th6,956.12,413.5 288.2%   
Avg. wages/employee Rs Th902.5523.2 172.5%   
Avg. net profit/employee Rs Th-1,993.0152.4 -1,307.3%   
INCOME DATA
Net Sales Rs m19,47732,106 60.7%  
Other income Rs m407226 180.4%   
Total revenues Rs m19,88432,332 61.5%   
Gross profit Rs m1,1034,448 24.8%  
Depreciation Rs m2,5191,730 145.7%   
Interest Rs m5,227241 2,170.6%   
Profit before tax Rs m-6,2362,703 -230.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125675 -18.5%   
Profit after tax Rs m-5,5802,028 -275.2%  
Gross profit margin %5.713.9 40.9%  
Effective tax rate %2.025.0 8.0%   
Net profit margin %-28.76.3 -453.6%  
BALANCE SHEET DATA
Current assets Rs m11,01417,340 63.5%   
Current liabilities Rs m32,0609,559 335.4%   
Net working cap to sales %-108.124.2 -445.9%  
Current ratio x0.31.8 18.9%  
Inventory Days Days95100 94.6%  
Debtors Days Days3457 59.0%  
Net fixed assets Rs m29,44020,779 141.7%   
Share capital Rs m705252 279.1%   
"Free" reserves Rs m2,04324,499 8.3%   
Net worth Rs m3,80024,553 15.5%   
Long term debt Rs m9,0183,517 256.4%   
Total assets Rs m46,51039,595 117.5%  
Interest coverage x-0.212.2 -1.6%   
Debt to equity ratio x2.40.1 1,656.6%  
Sales to assets ratio x0.40.8 51.6%   
Return on assets %-0.85.7 -13.3%  
Return on equity %-146.98.3 -1,777.9%  
Return on capital %-3.710.5 -35.6%  
Exports to sales %37.948.6 77.9%   
Imports to sales %22.614.2 158.9%   
Exports (fob) Rs m7,37815,617 47.2%   
Imports (cif) Rs m4,4064,571 96.4%   
Fx inflow Rs m7,51315,617 48.1%   
Fx outflow Rs m5,6495,828 96.9%   
Net fx Rs m1,8659,790 19.0%   
CASH FLOW
From Operations Rs m1,6822,764 60.8%  
From Investments Rs m-9,860-1,432 688.7%  
From Financial Activity Rs m6,644-1,591 -417.5%  
Net Cashflow Rs m-1,535-259 593.1%  

Share Holding

Indian Promoters % 32.3 45.9 70.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.4 40.4%  
FIIs % 3.3 25.3 13.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.4 317.8%  
Shareholders   84,811 36,892 229.9%  
Pledged promoter(s) holding % 54.9 2.1 2,566.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   SUVEN LIFE  SHASUN PHARMA  NOVARTIS  TTK HEALTHCARE  SUN PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jun 22, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - DR. DATSONS LABS COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS